(Q34769975)

4 August 2017

1 reference

title

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil (English)

1 reference

4 August 2017

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

8

Besser GM

1 reference

4 August 2017

7

Grossman AB

1 reference

4 August 2017

Kaltsas GA

1

1 reference

4 August 2017

Mukherjee JJ

2

1 reference

4 August 2017

Isidori A

3

1 reference

4 August 2017

Kola B

4

1 reference

4 August 2017

Plowman PN

5

1 reference

4 August 2017

Monson JP

6

1 reference

4 August 2017

publication date

1 August 2002

1 reference

4 August 2017

published in

Clinical Endocrinology

1 reference

4 August 2017

volume

57

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

169-183

1 reference

Treatment of liver metastases of carcinoid tumors

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Gastrointestinal endocrine tumours: medical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Nuclear medicine applications for neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Tumor markers in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Clinical experience over 48 years with pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Advances and controversies in the diagnosis and management of medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

An analysis of 8305 cases of carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Long-term survival after diagnosis of hepatic metastatic VIPoma: report of two cases with disparate courses and review of therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Treatment of medullary thyroid carcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Chemotherapy in the treatment of neuroendocrine malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Pancreatic endocrine tumours, immunotherapy and gene therapy: chemotherapy and interferon therapy of endocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Current approaches and perspectives in the therapy of medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2265.2002.01589.X

10.1046/J.1365-2265.2002.01589.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference